|
Diabetes Care, Vol 21, Issue 5 717-724, Copyright © 1998 by American Diabetes Association
Moderate intake of n-3 fatty acids for 2 months has no detrimental effect on glucose metabolism and could ameliorate the lipid profile in type 2 diabetic men. Results of a controlled study
J Luo, SW Rizkalla, H Vidal, JM Oppert, C Colas, A Boussairi, M Guerre-Millo, AS Chapuis, A Chevalier, G Durand and G Slama
Department of Diabetes, INSERM U341, Hotel-Dieu, Paris, France.
OBJECTIVE: To evaluate the effect of a moderate dose of fish oil on
glycemic control and in vivo insulin action in type 2 diabetic men with
elevated plasma triacylglycerols and to determine the effect of the same
treatment on gene expression of GLUT4, lipoprotein lipase (LPL), and
hormone-sensitive lipase (HSL) in the abdominal adipose tissue. RESEARCH
DESIGN AND METHODS: A total of 12 type 2 diabetic men were randomly
allocated to 2 months of 6 g daily of either fish oil or sunflower oil,
separated by a 2-month washout interval, in a double-blind crossover
design. RESULTS: For glucose metabolism, 2 months of fish oil
supplementation compared with sunflower oil led to similar fasting plasma
insulin, glucose, and HbA1c. Basal hepatic glucose production did not
increase after fish oil. There was no difference in insulin suppression of
hepatic glucose production nor in insulin stimulation of whole-body glucose
disposal measured by the euglycemic-hyperinsulinemic clamp. Fish oil did
not ameliorate the low mRNA level of GLUT4 in adipose tissue of these
patients. For lipid profile, fish oil lowered plasma triacylglycerol more
than sunflower oil (P < 0.05) and tended to increase the amount of mRNA
of both LPL and HSL in adipose tissue. CONCLUSIONS: A moderate dose of fish
oil did not lead to deleterious effects on glycemic control or whole-body
insulin sensitivity in type 2 diabetic men, with preserved
triacylglycerol-lowering capacities.

CiteULike Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. Kabir, G. Skurnik, N. Naour, V. Pechtner, E. Meugnier, S. Rome, A. Quignard-Boulange, H. Vidal, G. Slama, K. Clement, et al.
Treatment for 2 mo with n 3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study
Am. J. Clinical Nutrition,
December 1, 2007;
86(6):
1670 - 1679.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. De Caterina, R. Madonna, A. Bertolotto, and E. B. Schmidt
n-3 Fatty Acids in the Treatment of Diabetic Patients: Biological rationale and clinical data
Diabetes Care,
April 1, 2007;
30(4):
1012 - 1026.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. L Mostad, K. S Bjerve, M. R Bjorgaas, S. Lydersen, and V. Grill
Effects of n-3 fatty acids in subjects with type 2 diabetes: reduction of insulin sensitivity and time-dependent alteration from carbohydrate to fat oxidation.
Am. J. Clinical Nutrition,
September 1, 2006;
84(3):
540 - 550.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. McAuley and J. Mann
Thematic review series: Patient-Oriented Research. Nutritional determinants of insulin resistance
J. Lipid Res.,
August 1, 2006;
47(8):
1668 - 1676.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Corporeau, C. L. Foll, M. Taouis, J.-P. Gouygou, J.-P. Berge, and J. Delarue
Adipose tissue compensates for defect of phosphatidylinositol 3'-kinase induced in liver and muscle by dietary fish oil in fed rats
Am J Physiol Endocrinol Metab,
January 1, 2006;
290(1):
E78 - E86.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Fletcher, K. Berra, P. Ades, L. T. Braun, L. E. Burke, J. L. Durstine, J. M. Fair, G. F. Fletcher, D. Goff, L. L. Hayman, et al.
Managing Abnormal Blood Lipids: A Collaborative Approach
Circulation,
November 15, 2005;
112(20):
3184 - 3209.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Park, P. G Jones, and W. S Harris
Triacylglycerol-rich lipoprotein margination: a potential surrogate for whole-body lipoprotein lipase activity and effects of eicosapentaenoic and docosahexaenoic acids
Am. J. Clinical Nutrition,
July 1, 2004;
80(1):
45 - 50.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Tiikkainen, R. Bergholm, A. Rissanen, A. Aro, I. Salminen, M. Tamminen, K. Teramo, and H. Yki-Jarvinen
Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women
Am. J. Clinical Nutrition,
January 1, 2004;
79(1):
22 - 30.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J Woodman, T. A Mori, V. Burke, I. B Puddey, G. F Watts, and L. J Beilin
Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension
Am. J. Clinical Nutrition,
November 1, 2002;
76(5):
1007 - 1015.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Petersen, H. Pedersen, A. Major-Pedersen, T. Jensen, and P. Marckmann
Effect of Fish Oil Versus Corn Oil Supplementation on LDL and HDL Subclasses in Type 2 Diabetic Patients
Diabetes Care,
October 1, 2002;
25(10):
1704 - 1708.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Khan, A.-M. Minihane, P. J. Talmud, J. W. Wright, M. C. Murphy, C. M. Williams, and B. A. Griffin
Dietary long-chain n-3 PUFAs increase LPL gene expression in adipose tissue of subjects with an atherogenic lipoprotein phenotype
J. Lipid Res.,
June 1, 2002;
43(6):
979 - 985.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1998 by the American Diabetes Association.
|
|
| |
|